Center for Biomedical Testing (CBT) is a GLP-compliant CRO providing integrated preclinical services from early discovery through IND/NDA submission.

Our experienced scientists specialize in analytical and bioanalytical chemistry, pharmacokinetics (PK/ADME), toxicology, and pharmacology.

CBT laboratories deliver high-quality, regulatory-ready data to the biotechnology and pharmaceutical research community. We support programs from early discovery through Investigational New Drug (IND) and New Drug Application (NDA) submission.

As a contract research organization (CRO), CBT offers comprehensive Good Laboratory Practice (GLP)-compliant services, including acute, subchronic, and chronic toxicity, genotoxicity, reproductive toxicity, ADME, and PK studies. We also provide in vivo disease models (oncology, diabetes, inflammation, infection, kidney and liver injury) and analytical/bioanalytical support for drug development.

In addition, CBT offers advanced in vitro testing using human-relevant systems, including 3D skin models, ocular irritation assays, inhalation toxicity models, and platelet aggregation assays (PRP and whole blood).

CBT has successfully developed full IND-enabling programs for multiple test articles accepted by the FDA, with compounds advancing into Phase 1–3 clinical trials. We continue to support these programs with non-clinical and clinical PK studies.